Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904

Robert L. Coleman, James Moon, Anil K. Sood, Wei Hu, James E. Delmore, Albert J. Bonebrake, Garnet L. Anderson, Setsuko K. Chambers, Maurie Markman

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET, which has demonstrated clinical activity as a single agent and in combination with taxanes. We explored the efficacy, safety and toxicity of docetaxel and vandetanib in women with recurrent ovarian cancer (OC). Methods Women with refractory or progressive OC were randomised 1:1 to docetaxel (75 mg/m2, IV) + vandetanib (100 mg daily, PO, D + V) or docetaxel (75 mg/m2, D). Up to three additional cytotoxic regimens for recurrence and prior anti-angiogenic agents (as primary therapy) were allowed. The primary end-point was progression free survival (PFS). The study had 84% power to detect a PFS hazard ratio of 0.65, using a one-sided P of 0.1. This corresponds to an increase in median PFS from 3.6 months to 5.6 months. Patients progressing on D were allowed to receive single agent vandetanib (D → V). Results 131 Patients were enrolled; two were excluded. 16% had received prior anti-angiogenic therapy. The median PFS estimates were 3.0 mos (D + V) versus 3.5 (D); HR: 0.99 (80% CI: 0.79-1.26). 61 Patients on D + V were assessable for toxicity; 20(33%) had treatment-related Grade (G) 4 events, primarily haematologic. Similarly, 17 (27%) of 64 patients receiving D had G4 events, primarily haematologic. 27 Evaluable patients crossed-over to V. 1/27(4%) experienced a G4 event. G3 diarrhoea was observed in 4% D → V patients. Median OS was 14 mos (D + V) versus 18 mos (D → V); HR(OS): 1.25 (80% CI: 0.93-1.68). Crossover vandetanib response was 4% (1/27 evaluable patients). High plasma IL-8 levels were associated with response to D + V. Conclusions Combination docetaxel + vandetanib did not prolong PFS relative to docetaxel alone in OC patients. No unexpected safety issues were identified.

Original languageEnglish (US)
Pages (from-to)1638-1648
Number of pages11
JournalEuropean Journal of Cancer
Volume50
Issue number9
DOIs
StatePublished - Jun 2014

Keywords

  • Chemotherapy
  • Clinical trial
  • Epithelial cancer
  • Fallopian tube cancer
  • Ovarian cancer
  • Primary peritoneal cancer
  • Randomised phase II
  • Taxanes
  • Vandetanib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904'. Together they form a unique fingerprint.

Cite this